Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

ABSTRACT:

Purpose

Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as ramucirumab. The aim of this study was to retrospectively evaluate if occurrence of HTN is correlated with response to second line treatment with ramucirumab+paclitaxel for metastatic gastric cancer.

Methods

Treatment consisted of ramucirumab 8 mg/kg intravenously (iv) on days 1 and 15, plus paclitaxel 80 mg/m² iv on days 1, 8, and 15 of a 28-day cycle. Patients received study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.

Results

Thirty-four patients were retrospectively evaluated. Among these, 6 (17.6%) developed grade 3 ramucirumab-induced HTN. These patients h

SUBMITTER: Roviello G 

PROVIDER: S-EPMC5976467 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature